Author: Ellis Neufeld MD PhD and Stacy Croteau MD MMS

Dose recommendations for new extended half-life hemophilia factor products fall short

hemophilia extended life factor blood cells
(Gotzila Freedom/Shutterstock)

We, like many in the hemophilia community, were excited to see extended half-life (EHL) factor VIII and IX products start coming to market over the last few months. These products—and expected future products—promise equivalent or greater prophylactic bleeding control with fewer infusions, and so could greatly enhance patients’ quality of life.

Yet, as we noted in our recent editorial in Haemophilia, we are greatly concerned that patients and providers, seeing the opportunity to reduce their infusion burden, will opt for a dosing strategy that may not benefit patients clinically or financially. …Read More

Read Full Story | Leave a Comment